

ALK Investor Relations Department BÃ,ge Alle 6-8 Horsholm DK-2970 Denmark

Visit IR website ☐ Sign-up for Email alerts ☐

OMX: ALKB Last Trade: 749.00 Trade Time: 4:59 PM ET Apr 25, 2018 Change: 0.00 (0.000%) Day Range N/A - N/A 52-Week Range 646.00 - 1133.00 Volume N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

ALK is the world leader in allergy vaccination (immunotherapy). It is the goal of ALK to increase the awareness of the company and its activities through a structured, ongoing, timely and balanced dialogue with investors, shareholders and other stakeholders. It is also a company goal to secure the liquidity of the company's shares and to generate reasonable, long-term returns to shareholders through share price increases and dividends.... (more)

Company releases [View all]

Apr 17, 2018

<u>ALK's partner for Japan, Torii, secures</u> pricing for new Japanese cedar SLIT-tablet

Apr 11, 2018

ALK announces allergy diagnostic partnership with Rellergen in China

Mar 20, 2018

Report on transactions with ALK-Abelló A/S
B-shares and associated securities by
managerial staff

Mar 20, 2018

Grant of share options and performance shares to members of the Board of Management and key employees

Mar 16, 2018 Articles of Association

Upcoming Events [View all]

May 4, 2018

Three-month interim report (Q1) 2018

May 7, 2018

IR roadshow, Copenhagen